Version May 2024
Ophthalmic procedures: Ophthalmic: Instill 1 or 2 drops in the eye as needed.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
(For additional information see "Fluorescein and benoxinate: Pediatric drug information")
Ophthalmic procedures: Infants, Children, and Adolescents: Ophthalmic: Instill 1 or 2 drops into each eye as needed before procedure.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Ophthalmic: Blurred vision, burning sensation of eyes, eye irritation, ocular hyperemia, punctate keratitis, stinging of eyes
Hypersensitivity to fluorescein, benoxinate, or any component of the formulation
Other warnings/precautions:
• Appropriate use: For topical ophthalmic use only. To avoid contamination, do not touch dropper tip to eyelids or other surfaces. The anesthetized eye should be protected from irritation, foreign bodies, and rubbing to prevent inadvertent damage.
• Prolonged use: Prolonged use or abuse may lead to corneal epithelial toxicity, manifesting as epithelial defects, which may progress to permanent corneal damage and vision loss.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Ophthalmic:
Altafluor: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% (5 mL [DSC])
Altafluor Benox: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% (5 mL) [contains chlorobutanol (chlorobutol)]
Generic: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% (5 mL); Fluorescein sodium 0.3% and benoxinate hydrochloride 0.4% (5 mL)
Yes
Solution (Fluorescein-Benoxinate Ophthalmic)
0.25-0.4% (per mL): $1.57
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Ophthalmic:
Fluress: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% ([DSC])
Generic: Fluorescein sodium 0.25% and benoxinate hydrochloride 0.4% ([DSC])
Ophthalmic: For topical ophthalmic use only; avoid touching tip of dropper to eye, fingers, or other surfaces. Avoid touching eye for ~20 minutes after instillation; protect eye from irritation, chemicals, foreign bodies, and rubbing to prevent inadvertent damage.
Ophthalmic: For topical ophthalmic use only; avoid touching tip of dropper to eye, fingers, or other surfaces. Avoid touching eye for ~20 minutes after instillation; anesthetic effects decrease sensitivity and may increase risk of injury; protect eye from irritation, chemicals, foreign bodies, and rubbing to prevent inadvertent damage.
Ophthalmic procedures: For use in ophthalmic procedures when a topical disclosing agent is needed along with an anesthetic.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Acetylcholinesterase Inhibitors: May enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. Risk C: Monitor therapy
BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine. Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand). Risk C: Monitor therapy
BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal). Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine. Risk X: Avoid combination
Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics. Risk C: Monitor therapy
Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy
Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy
Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept. Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics. This interaction does not appear to apply to other uses of these agents in combination. Risk C: Monitor therapy
Animal reproduction studies have not been conducted. Refer to Fluorescein monograph.
According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Refer to Fluorescein monograph.
Fluorescein is a diagnostic dye; benoxinate is a rapid acting anesthetic with short duration.
Onset of action: 5 to 45 seconds
Duration: ~20 minutes (single administration); effect may be prolonged by subsequent administration (10 to 20 minutes after last administration)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
